once monthly glp 1 Ascletis Pharma Selects ASC35 as Once-Monthly GLP-1/GIP Dual Agonist Candidate for Obesity Treatment New study on experimental once-monthly

2023: Ozempic and Wegovy are listed on FDAs Durg Shortages list

Age is another major risk factor: HF has been reported to affect around 1%2% of all adults (Weldy and Ashley, 2021)

Ozempic (semaglutide) is a valuable option for many of our patients with type 2 diabetes

Not everyone who wants to microdose should

Wei and colleagues (Wei et al., 2022) recently discovered that GLP-1 receptor activation inhibits this signaling pathway by modulating ROCK activity, leading to a reduction in the phosphorylation of MLC, which stabilizes the endothelial cell cytoskeleton and tight junctions by upregulating the expression of tight junction proteins such as Occludin and ZO-1

Fracture risk after three bariatric surgery procedures in Swedish obese subjects: up to 26 years follow-up of a controlled intervention study